现代中西医结合杂志2025，Vol.34Issue(23)：3238-3243,6.DOI:10.3969/j.issn.1008-8849.2025.23.005
基于神经营养因子和脑肠肽探讨巴戟天寡糖胶囊治疗肠易激综合征的效应机制
Mechanism of morinda officinalis oligosaccharide capsule in the treatment of irritable bowel syndrome based on the regulation of intestinal tissue neurotrophic factors and brain gut peptide proteins
摘要
Abstract
Objective It is to explore the effect and mechanism of morinda officinalis oligosaccharide capsule in the treatment of irritable bowel syndrome(IBS)based on intestinal tissue neurotrophic factors and brain gut peptide proteins.Methods Seventy-two male SD rats were taken,12 of which were randomly selected as blank group,and the rest of the ani-mals were prepared by chronic unpredictable stimulation method to establish IBS models.At 2 weeks after modeling,the modeled rats were randomly divided into model group,pinaverium bromide tablet group,and high,medium,and low-dose groups of morinda officinalis oligosaccharide capsule,with 12 rats in each group.The piperazine bromide tablet group was treated with piperazine bromide tablet suspension at a dose of 20 mg/kg by gavage,the high-,medium-,and low-dose groups of morinda citrifolia oligosaccharide capsules were treated with morinda citrifolia oligosaccharide capsule suspension at doses of 60 mg/kg,30 mg/kg,and 15 mg/kg by gavage,respectively,all continuously administrated for 2 weeks.At 2 weeks after modeling and 2 weeks after gavage,the abdominal withdrawal reflex(AWR)threshold of the rats in each group were detected;after 2 weeks of gavage,the fecal water content of the rats in each group was measured,the contents of sub-stance P(SP)and vasoactive intestinal peptide(VIP)in colonic tissue were measured by ELISA,the positive expression of c-Fos in colonic tissue was detected by immunohistochemistry,and the protein expressions of brain-derived neurotrophic factor(BDNF)and neurotrophic factor 3(NT3)in colonic tissue were detected by Western blot analysis.Results At 2 weeks after modeling,the AWR thresholds of the rats in all modeled groups were significantly lower than those in the con-trol group(all P<0.05);after 2 weeks of gavage,the AWR threshold of rats in the model group was significantly lower than that in the control group(P<0.05),while those in all medicated groups were significantly higher than that in the model group(all P<0.05).The content of fecal water,contents of SP and VIP in colon tissue,mean optical density value of c-Fos positive expression in colon tissue,and relative protein expressions of BDNF and NT3 in colon tissue of the rats in the model group were significantly higher than those in the blank group(all P<0.05);the content of fecal water,contents of SP and VIP in colon tissue,mean optical density value of c-Fos positive expression in colon tissue,and relative protein expressions of BDNF and NT3 in colon tissue of the rats in the high-dose group of morinda officinalis oligosaccharide cap-sule,medium-dose group of morinda officinalis oligosaccharide capsule(except for content of fecal water),and pinaverium bromide tablet group were significantly lower than those in the model group(all P<0.05),only the mean optical density of c-Fos positive expression and the relative protein expression of BDNF in colon tissue of the rats in the low-dose group of morinda officinalis oligosaccharide capsule were significantly lower than those in the model group(all P<0.05).Conclu-sion Morinda officinalis oligosaccharide capsule can effectively significantly reduce visceral hypersensitivity and alleviate di-arrhea of rats with IBS.Its effect mechanism in the treatment of IBS may be related to reduced brain gut peptide proteins in colonic tissue and down-regulate the expressions of neurotrophic factors.关键词
肠易激综合征/巴戟天寡糖胶囊/内脏敏感性/P物质/血管活性肠肽/脑源性神经营养因子/神经营养因子3Key words
irritable bowel syndrome/morinda officinalis oligosaccharide capsule/visceral sensitivity/substance P/vasoactive intestinal peptide/brain-derived neurotrophic factor/neurotrophic factor分类
医药卫生引用本文复制引用
刘珊珊,朱晓光,张晓笛,翟建英,李晋生..基于神经营养因子和脑肠肽探讨巴戟天寡糖胶囊治疗肠易激综合征的效应机制[J].现代中西医结合杂志,2025,34(23):3238-3243,6.基金项目
国家科技重大专项(2014ZX09301307-014) （2014ZX09301307-014）
北京市科技计划项目(Z141100005714015) （Z141100005714015）
北京市中医药科技发展资金项目(BJZYYB-2023-70) （BJZYYB-2023-70）
